伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察

doi:10.3969/j.issn.1000-8535.2024.05.006

广州医药 ›› 2024, Vol. 55 ›› Issue (5): 489-493.DOI: 10.3969/j.issn.1000-8535.2024.05.006

伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察

李思荃, 蔡祥胜, 张伟铮, 胡笑仪, 孙宁, 许研

广州市干部和人才健康管理中心,广州市第十一人民医院（广东广州 510530）

收稿日期:2024-01-03 出版日期:2024-05-20 发布日期:2024-06-28
通讯作者: 许研,E-mail：346356961@qq.com;孙宁,E-mail：ning.sun@connect.polyu.hk
基金资助:
国家自然科学基金（81703333）; 广东省自然科学基金（2020A1515011326）

Efficacy of vonoprazan triple therapy for treatment of Helicobacter pylori

LI Siquan, CAI Xiangsheng, ZHANG Weizheng, HU Xiaoyi, SUN Ning, XU Yan

Guangzhou Cadre and Talent Health Management Center（Guangzhou 11th People’s Hospital）,Guangzhou 510530,China

Received:2024-01-03 Online:2024-05-20 Published:2024-06-28

摘要/Abstract

摘要： 目的探究伏诺拉生三联疗法根除幽门螺杆菌（Hp）的疗效。方法入组2022年5月—12月经¹³C尿素呼气试验确诊的Hp现症感染者200例,分为观察组和对照组,每组100例。观察组方案为阿莫西林、呋喃唑酮、伏诺拉生三联疗法,对照组方案为阿莫西林、呋喃唑酮、艾司奥美拉唑镁、枸橼酸铋钾四联疗法;疗程均为14 d。在治疗停药后1个月复查¹³C尿素呼气试验判定是否Hp根除成功,并观察药物不良反应发生率。结果观察组Hp根除率为96.97%,高于对照组的89.80%,差异有统计学意义（P<0.05）;观察组不良反应发生率和对照组比较差异无统计学意义（P>0.05）。结论伏诺拉生、阿莫西林、呋喃唑酮三联疗法的Hp根除率较高且安全性良好,可作为Hp感染的治疗方案之一。

关键词: 伏诺拉生, 阿莫西林, 呋喃唑酮, 幽门螺杆菌, 三联疗法

Abstract: Objective To explore the effect of vonoprazan triple therapy on Helicobacter pylori（Hp）．Methods A total of 200 patients with Hp infection confirmed by ¹³C urea breath test from May-December 2022 were selected and divided into observation group and control group with 100 patients in each group．The observation group was treated with triple therapy of amoxicillin,furazolidone and vonoprazan,while the control group was treated with quadruple therapy of amoxicillin,furazolidone,esomeprazole magnesium and bismuth potassium citrate．The treatment course was 14 days．The ¹³C urea breath test was reviewed one month after treatment withdrawal to determine whether Hp eradication was successful,and the incidence of adverse drug reactions was observed．Results The eradication rate of Hp in the observation group was 96.97%,higher than 89.80% in the control group,and the difference was statistically significant（P<0.05）．There was no significant difference in the incidence of adverse reactions between the observation group and the control group（P>0.05）．Conclusions The triple therapy of vonoprazan,amoxicillin and furazolidone has a very high eradication rate and good safety,which can be used as one of the treatment options for Hp．

Key words: vonoprazan, amoxicillin, furazoldone, Helicobacter pylori, triple therapy

李思荃, 蔡祥胜, 张伟铮, 胡笑仪, 孙宁, 许研. 伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察[J]. 广州医药, 2024, 55(5): 489-493.

LI Siquan, CAI Xiangsheng, ZHANG Weizheng, HU Xiaoyi, SUN Ning, XU Yan. Efficacy of vonoprazan triple therapy for treatment of Helicobacter pylori[J]. Guangzhou Medical Journal, 2024, 55(5): 489-493.

参考文献

[1] 刘文忠,谢勇,陆红,等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2017,22(6):346-360.
[2] 李超,徐晓军,孔超美,等.幽门螺杆菌根除前及根除失败后耐药情况分析[J].胃肠病学和肝病学杂志,2022,31(4):383-385,396.
[3] 屈健,奉继运,张文达.三联疗法治疗幽门螺旋杆菌感染消化性溃疡的临床分析[J].广州医药,2010,41(6):27-28.
[4] KATO M,OTA H,OKUDA M,et al.Guidelines for the management of Helicobacter pylori infection in Japan:2016 Revised Edition[J].Helicobacter,2019,24(4):e12597.
[5] MARTIN,ZHOU Y,MENG C X,et al.Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding:A meta-analysis of randomized controlled trials and observational studies[J].Medicine(Baltimore).2020,99(9):e19357.
[6] TANABE H,ANDO K,SATO K, et al.Efficacy of vonoprazan-based triple therapy for helicobacter pylori eradication:A multicenter study and a review of the literature[J].Dig Dis Sci,2017,62(11):3069-3076.
[7] 国家消化系疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟(GECA),中华医学会消化病学分会幽门螺杆菌学组,等.中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年,上海)[J].中华消化杂志,2019,39(5):310-316.
[8] 中华医学会消化病学分会幽门螺杆菌学组.第六次全国幽门螺杆菌感染处理共识报告(非根除治疗部分)[J].中华消化杂志,2022,42(5):289-303.
[9] 彭卫斌,容海鹰,沙卫红,等.含益生菌四联疗法根除幽门螺杆菌的临床疗效[J].广州医药,2017,48(1):38-41.
[10] 周昱. 慢性胃炎合并Hp感染应用香砂六君子汤联合基础三联治疗的效果[J].中国医药科学,2023,13(22):85-88,128.
[11] 何小琦,罗承锋,刘月婵,等.中西医结合治疗HP相关性慢性胃炎的疗效分析[J].广州医药,2006(3):77-78.
[12] IERARDI E,LOSURDO G,FORTEZZA R F,et al.Optimizing proton pump inhibitors in Helicobacter pylori treatment:Old and new tricks to improve effectiveness[J].World J Gastroenterol,2019,25(34):5097-5104.
[13] SAKURAI Y,MORI Y,OKAMOTO H,et al.Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study[J].Aliment Pharmacol Ther,2015,42(6):719-730.
[14] FURUTA T,SHIRAI N,SUGIMOTO M,et al.Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies[J].Drug Metab Pharmacokinet,2005,20(3):153-167.
[15] MIFTAHUSSURUR M,PRATAMA PUTRA B,YAMAOKA Y.The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy[J].Pharmaceuticals(Basel),2020,13(10):276.
[16] SAKURAI Y,NISHIMURA A,KENNEDY G,et al.Safety,tolerability,pharmacokinetics,and pharmacodynamics of single rising TAK-438(vonoprazan)doses in healthy male Japanese/non-Japanese subjects[J].Clin Transl Gastroenterol,2015,6(6):e94.
[17] OTAKE K,SAKURAI Y,NISHIDA H,et al.Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate(TAK-438)[J].Adv Ther,2016,33(7):1140-1157.
[18] YAMASAKI H,KAWAGUCHI N,NONAKA M,et al.In vitro metabolism of TAK-438,vonoprazan fumarate,a novel potassium-competitive acid blocker[J].Xenobiotica,2017,47(12):1027-1034.
[19] DONG S Q,SINGH T P,WEI X,et al.Review:A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy:Is superiority an illusion?[J].Helicobacter,2017,22(6).
[20] GUNARATNE A W,HAMBLIN H,CLANCY A,et al.Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study[J].Helicobacter,2021,26(5):e12830.
[21] SUE S,SUZUKI N,SHIBATA W,et al.First-line helicobacter pylori eradication with vonoprazan,clarithromycin,and metronidazole in patients allergic to penicillin[J].Gastroenterol Res Pract,2017(2017):2019802.
[22] MARUYAMA M,TANAKA N,KUBOTA D,et al.Vonoprazan-based regimen is more useful than PPI-based one as a first-line helicobacter pylori eradication:A randomized controlled trial[J].Can J Gastroenterol Hepatol,2017(2017):4385161.
[23] 陈剑. 伏诺拉生与阿莫西林二联治疗幽门螺杆菌感染胃溃疡的疗效和安全性[J].中国实用医药,2021,16(1):125-127.
[24] 王先令,周国强,林琳,等.伏诺拉生联合阿莫西林、克拉霉素三联七日疗法根除幽门螺杆菌的临床研究[J].实用医学杂志,2022,38(10):1271-1275.
[25] 王丽娜,张田,曹娅,等.伏诺拉生根除幽门螺杆菌感染的快速卫生技术评估[J].临床药物治疗杂志,2022,20(10):17-22.

伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察

Efficacy of vonoprazan triple therapy for treatment of Helicobacter pylori

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	蒋伟峰, 刘雨露, 王战胜. 阿莫西林克拉维酸钾联合第三代头孢类抗菌药治疗新生儿肺炎的临床效果及其对肠道菌群的影响[J]. 广州医药, 2024, 55(2): 176-180.
[2]	刘文霞, 张晓. 阿莫西林克拉维酸钾干混悬剂(7:1)联合胸腺肽治疗支气管哮喘合并肺部感染患儿的疗效[J]. 广州医药, 2020, 51(3): 136-138.
[3]	罗曼虹. 加减香砂六君子汤联合三联疗法治疗慢性萎缩性胃炎临床观察[J]. 广州医药, 2019, 50(1): 28-32.
[4]	张春燕, 张赐理. 幽门螺杆菌感染与儿童过敏性紫癜患病及预后的相关性研究[J]. 广州医药, 2018, 49(4): 79-81.
[5]	彭卫斌, 容海鹰, 沙卫红, 聂玉强, 杨元生, 李锐清, 朱雅丽, 张明. 含益生菌四联疗法根除幽门螺杆菌的临床疗效[J]. 广州医药, 2017, 48(1): 38-41.
[6]	陈航远, 谭其平, 蒋宇敏. 含多西环素四联疗法对幽门螺杆菌感染消化性溃疡的疗效研究[J]. 广州医药, 2016, 47(5): 86-87.
[7]	周丽丽, 魏良洲. 幽门螺杆菌感染与反流性食管炎关系的研究[J]. 广州医药, 2016, 47(1): 46-48.
[8]	黄鲁, 沈洁. 幽门螺杆菌感染与年龄及血脂异常的相关性[J]. 广州医药, 2016, 47(1): 75-77.